Drug Price Transparency Act

3.0.0 2113 2023-01-11T13:44:08Z 2023-01-11T13:44:08Z House HR 2019-04-08 116 [Congressional Record Volume 165, Number 60 (Monday, April 8, 2019)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mr. NEAL:H.R. 2113.Congress has the power to enact this legislation pursuantto the following:Article 1, Section 8, Clause 1[Page H3129]]]> hsif00 Energy and Commerce Committee House Standing hsif14 Health Subcommittee Referred to 2019-04-09T19:02:15Z Discharged from 2020-12-24T14:49:37Z Referred to 2019-04-08T16:00:52Z hswm00 Ways and Means Committee House Standing hswm02 Health Subcommittee Referred to 2019-04-08T15:23:16Z Reported by 2020-12-24T14:48:48Z Markup by 2019-04-09T15:31:25Z Referred to 2019-04-08T16:00:47Z H. Rept. 116-688 Drug Price Transparency Act 116 2087 HR 2019-05-21 Subcommittee Hearings Held. Related bill CRS Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act 116 2115 HR 2019-10-29 Received in the Senate and Read twice and referred to the Committee on Finance. Related bill CRS Strengthening Average Sales Price Reporting Act of 2019 116 2051 S 2019-06-28 Read twice and referred to the Committee on Finance. Related bill CRS To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes. 116 2064 HR 2019-05-21 Subcommittee Hearings Held. Related bill CRS SPIKE Act 116 2069 HR 2019-05-21 Subcommittee Hearings Held. Related bill CRS 2020-12-24 Placed on the Union Calendar, Calendar No. 571. Calendars H12410 2 House floor actions U00571 2020-12-24 Committee on Energy and Commerce discharged. Discharge H12300 2 House floor actions hsif00 Energy and Commerce Committee 2020-12-24 Committee on Energy and Commerce discharged. Committee 5500 9 Library of Congress hsif00 Energy and Commerce Committee 2020-12-24 Reported (Amended) by the Committee on Ways and Means. H. Rept. 116-688, Part I. Committee H12200 2 House floor actions hswm00 Ways and Means Committee 2020-12-24 Reported (Amended) by the Committee on Ways and Means. H. Rept. 116-688, Part I. Committee 5000 9 Library of Congress hswm00 Ways and Means Committee 2019-04-09 hsif14 Health Subcommittee 1 House committee actions Referred to the Subcommittee on Health. Committee 2019-04-09 hswm00 Ways and Means Committee 1 House committee actions Ordered to be Reported by Voice Vote. Committee 2019-04-09 hswm00 Ways and Means Committee 1 House committee actions Committee Consideration and Mark-up Session Held. Committee 2019-04-08 Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. IntroReferral H11100 2 House floor actions hsif00 Energy and Commerce Committee 2019-04-08 Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. IntroReferral H11100 2 House floor actions hswm00 Ways and Means Committee 2019-04-08 hswm02 Health Subcommittee 1 House committee actions Referred to the Subcommittee on Health. Committee 2019-04-08 Introduced in House IntroReferral Intro-H 9 Library of Congress 2019-04-08 Introduced in House IntroReferral 1000 9 Library of Congress N000015 Rep. Neal, Richard E. [D-MA-1] RICHARD NEAL D MA E. 1 N B000755 Rep. Brady, Kevin [R-TX-8] KEVIN BRADY R TX 8 2019-04-08 True V000133 Rep. Van Drew, Jefferson [D-NJ-2] Jefferson Van Drew D NJ 2 2019-04-15 False F000467 Rep. Finkenauer, Abby [D-IA-1] Abby Finkenauer D IA 1 2019-04-15 False H001085 Rep. Houlahan, Chrissy [D-PA-6] Chrissy Houlahan D PA 6 2019-04-18 False R000606 Rep. Raskin, Jamie [D-MD-8] Jamie Raskin D MD 8 2019-04-29 False M001209 Rep. McAdams, Ben [D-UT-4] Ben McAdams D UT 4 2019-05-02 False U000040 Rep. Underwood, Lauren [D-IL-14] Lauren Underwood D IL 14 2019-05-07 False S001208 Rep. Slotkin, Elissa [D-MI-8] Elissa Slotkin D MI 8 2019-05-15 False L000563 Rep. Lipinski, Daniel [D-IL-3] Daniel Lipinski D IL William 3 2019-05-22 False L000397 Rep. Lofgren, Zoe [D-CA-19] ZOE LOFGREN D CA 19 2019-06-13 False A000369 Rep. Amodei, Mark E. [R-NV-2] Mark Amodei R NV E. 2 2019-11-05 False 2019-06-25T20:05:23Z H.R. 2113, Prescription Drug STAR Act https://www.cbo.gov/publication/55392 As ordered reported by the House Committee on Ways and Means on April 9, 2019 Health Business records Civil actions and liability Congressional oversight Corporate finance and management Government information and archives Health care costs and insurance Inflation and prices Manufacturing Medicare Prescription drugs Health

00 2019-04-08 Introduced in House 2020-07-22T15:09:38Z Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or the Prescription Drug STAR Act

This bill establishes requirements for prescription drug manufacturers to provide certain information about pricing, discounts, and product samples of applicable drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to annually determine whether there are price increases of a certain threshold for outpatient prescription drugs covered under Medicare, excluding low-cost drugs.

Manufacturers must provide HHS with an explanation for drug prices that (1) cumulatively increase by at least 10% or $10,000 over one year; (2) cumulatively increase by at least 25% or $25,000 over three years; or (3) are at least $26,000 annually, per individual, if first covered by Medicare during the applicable year. The manufacturer must explain the role of the factors contributing to such prices and other relevant information, including manufacturing costs, marketing costs, and revenue.

Additionally, drug manufacturers must provide HHS with aggregate data related to product samples of drugs, devices, biologic products, and medical supplies given to hospitals, physicians, or other medical professionals during the previous calendar year, beginning in 2023.

The bill further requires HHS to make publicly available the information related to drug discounts, rebates, and price concessions that is provided annually to HHS by group health plans. Drug manufacturers also must report to HHS certain sales information for drugs available under Medicare for which the manufacturer does not have a rebate agreement in place.

The bill requires HHS to study and report on trends concerning inpatient hospital drug costs.

]]>

08 2020-12-24 Reported to House, Part I 2021-01-22T20:59:54Z Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or the Prescription Drug STAR Act

This bill establishes requirements for prescription drug manufacturers to provide certain information about pricing, discounts, and product samples of applicable drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to annually determine whether there are price increases of a certain threshold for outpatient prescription drugs covered under Medicare, excluding low-cost drugs.

Manufacturers must provide HHS with an explanation for drug prices that (1) cumulatively increase by at least 10% or $10,000 over one year; (2) cumulatively increase by at least 25% or $25,000 over three years; or (3) are at least $26,000 annually, per individual, if first covered by Medicare during the applicable year. The manufacturer must explain the role of the factors contributing to such prices and other relevant information, including manufacturing costs, marketing costs, and revenue.

]]>

Prescription Drug STAR Act Display Title Prescription Drug STAR Act Official Title as Introduced To amend titles XI and XVIII of the Social Security Act to provide for drug manufacturer price transparency, to require certain manufacturers to report on product samples provided to certain health care providers, and for other purposes. Reported in House RH Short Title(s) as Introduced Prescription Drug STAR Act Introduced in House IH Short Title(s) as Introduced Prescription Drug Sunshine, Transparency, Accountability and Reporting Act Introduced in House IH Short Title(s) as Reported to House Prescription Drug STAR Act H House Reported in House RH Short Title(s) as Reported to House Prescription Drug Sunshine, Transparency, Accountability and Reporting Act H House Reported in House RH Reported in House 2020-12-24T05:00:00Z https://www.govinfo.gov/content/pkg/BILLS-116hr2113rh/xml/BILLS-116hr2113rh.xml Introduced in House 2019-04-08T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-116hr2113ih/xml/BILLS-116hr2113ih.xml 2020-12-24 Placed on the Union Calendar, Calendar No. 571. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.